Screening of the small molecule library of Meinox enables the identification of anticancer compounds in pathologically distinct cancers
Screening of the small molecule library of Meinox enables the identification of anticancer compounds in pathologically distinct cancers
Small molecules are widely used for the modulation of the molecular basis of diseases. This makes them the perfect tool for discovering and developing new therapeutics. In this work, we have established a library of small molecules in house and characterized its molecular and druglike properties. We have shown that most small molecules have molecular weights less than 450. They have pharmaceutically relevant cLogP, cLogS, and druglikeness value distributions. In addition, Meinox’s small molecule library contained small molecules with polar surface areas that are less than 60 square angstroms, suggesting their potent ability to cross the bloodbrain barrier. Meinox’s small molecule library was also tested in vitro for pathologically distinct forms of cancer, including pancreatic adenocarcinoma PANC1, breast carcinoma MCF7, and lymphoblastic carcinoma RS4-11 cell lines. Analysis of this library at a dose of 1 μM allowed the discovery of potent, specific or broadly active anticancer compounds against pathologically distinct cancers. This study shows that in vitro analysis of different cancers or other phenotypic assays with Meinox small molecule library may generate novel and potent bioassay-specific compounds.
___
- Bakhshaliyev N, Uluganyan M, Enhos A, Karacop E, Ozdemir R (2020). The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. Journal of Electrocardiology 62: 59-64.
- Barreca M, Spanò V, Montalbano A, Cueto M, Díaz Marrero AR et al. (2020). Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. Marine drugs 18: 619.
- Bayram B, Ozgur A, Tutar L, Tutar Y (2018). Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs. Current Pharmaceutical Design 23 (35): 5349-5357.
- Beksac M, Balli S, Akcora Yildiz D (2020). Drug Targeting of Genomic Instability in Multiple Myeloma. Frontiers in Genetics 9 (11): 228. doi: 10.3389/fgene.2020.00228
- Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F et al. (2013). Synergistic Interaction of Paclitaxel and Curcumin with Cyclodextrin Polymer Complexation in Human Cancer Cells. Molecular Pharmaceutics 10 (7): 2676-83. doi: 10.1021/ mp400101k
- Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F et al. (2013). Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Molecular Pharmaceutics 10: 2676-2683.
- Coussens NP, Braisted JC, Peryea T, Sittampalam GS, Simeonov A et al. (2017). Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration–Approved Drugs. Pharmacological Reviews 69: 479-496.
- Daglioglu C (2017). Enhancing Tumor Cell Response to Multidrug Resistance with pH-Sensitive Quercetin and Doxorubicin Conjugated Multifunctional Nanoparticles. Colloids and Surfaces B: Biointerfaces 156: 175-185.
- Demirel HC, Dogan T, Tuncbag N (2018). A Structural Perspective on the Modulation of Protein-Protein Interactions with Small Molecules. Current Topics in Medicinal Chemistry 18: 700- 713. Ersek A, Xu K, Antonopoulos A, Butters TD, Santo AE et al. (2015). Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. Journal of Clinical Investigation 125: 2279-2292.
- Gökbulut AA, Yaşar M, Baran Y (2015). A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells. Turkish Journal of Hematology 32: 118-126.
- Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S et al. (2014). Nucleo-cytoplasmic transport as a therapeutic target of cancer. Journal of Hematology & Oncology 7: 85.
- Kacı FN, Kiraz Y, Çekdemir D, Baran Y (2020). Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells. Archives of Medical Research 51: 187-193.
- Kanan D, Kanan T, Dogan B, Orhan MD, Avsar T et al. (2020). An Integrated in silico Approach and in vitro Study for the Discovery of Small‐Molecule USP7 Inhibitors as Potential Cancer Therapies. ChemMedChem 16 (3): 555-567.
- Kara A, Özgür A, Tekin Ş, Tutar Y (2021). Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma. AntiCancer Agents in Medicinal Chemistry 2021 Feb 18. doi: 10.21 74/1871520621666210218175439
- Karpuz M, Silindir-Gunay M, Ozer AY (2018). Current and Future Approaches for Effective Cancer Imaging and Treatment. Cancer Biotherapy and Radiopharmaceuticals 33: 39-51.
- Kaymaz BT, Günel NS, Ceyhan M, Çetintaş VB, Özel B (2015). Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted “hsa-miR-2278” as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Tumor Biology 36: 7915- 7927.
- López-López E, Naveja JJ, Medina-Franco JL (2019). DataWarrior: an evaluation of the open-source drug discovery tool. Expert Opinion on Drug Discovery 14: 335-341.
- Mamdani H, Jalal SI (2020). Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope? Frontiers in Cell and Developmental Biology 9 (8): 582370. doi: 10.3389/ fcell.2020.582370
- Mohammadi E, Benfeitas R, Turkez H, Boren J, Nielsen J et al. (2020). Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning. Cancers 12: 2694.
- Noronha V, Sekhar A, Patil VM, Menon N, Joshi A et al. (2020). Systemic therapy for limited stage small cell lung carcinoma. Journal of thoracic disease 12: 6275-6290.
- Özenver N, Efferth T (2020). Small molecule inhibitors and stimulators of inducible nitric oxide synthase in cancer cells from natural origin (phytochemicals, marine compounds, antibiotics). Biochemical Pharmacology 176: 113792.
- Sadowski AR, Gardner HL, Borgatti A, Wilson H, Vail DM et al. (2018). Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Veterinary Research 14 (1): 250. doi: 10.1186/s12917- 018-1587-9
- Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R et al. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. International Journal of Molecular Sciences 18: 441.
- Turan RD, Albayrak E, Uslu M, Siyah P, Alyazici LY et al. (2020). Development of Small Molecule MEIS Inhibitors that modulate HSC activity. Scientific Reports 10: 7994.
- Zaka M, Abbasi BH, Durdagi S (2018). Novel tumor necrosis factor-α (TNF-α) inhibitors from small molecule library screening for their therapeutic activity profiles against rheumatoid arthritis using target-driven approaches and binary QSAR models. Journal of Biomolecular Structure and Dynamics 37: 2464- 2476.
- ISSN: 1300-0152
- Yayın Aralığı: Yılda 6 Sayı
- Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler
Arif MERMER, Aynura MAMMADOVA, Fatih KOCABAŞ
Zhirong WANG, Xiangjie KONG, Ming ZHU, Zhuoqun XU, Jianfeng SHAO
Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells
Ümit ZEYBEK, Cem İsmail KÜÇÜKALİ, Elif ERTÜRK, Ferda ARI, Oğuzhan AKGÜN, Engin ULUKAYA
Eda TAHİR TURANLI, Gökhan TERZİOĞLU, Gökçe ÇELİKYAPI ERDEM, Timucin AVŞAR
Analyzing differentially expressed genes and pathways of Bex2-deficient mouse lung via RNA-Seq
Noor BAHADAR, Hanif ULLAH, Salah ADLAT, Rajiv KUMAR SAH, May ZUN ZAW MYINT, Zin MAR OO, Fatoumata BINTA BAH, Farooq HAYEL NAGI, Hsu HTOO, Ahmad UD DIN, Xuechao FENG, Yaowu ZHENG